Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
Michelle XIA
Michelle XIA

Chairman, President & CEO


Akeso Biopharma

Dr. Michelle Xia has over 20 years of experience in biopharmaceutical R&D and academic research.  Prior to founding Akeso Biopharma, she was Senior Vice President at Crown Bioscience, in charge of the Biologics Business Unit and Pfizer-Crown Asian Cancer Research Center.  Prior to that Dr. Xia worked at PDL BioPharma (later acquired by AbbVie), one of the pioneer therapeutic antibody technology and drug development company in the San Francisco Bay Area.  At PDL, Dr. Xia served as a CMC core member overseeing drug product process development / manufacturing, and FDA registration / IND enabling process.  Prior to that Dr. Xia worked in the CMC Process Development Department of Bayer in Berkeley.  Her responsibilities included building the Pathogen Safety facility at Bayer and managing viral safety evaluation / process validation for manufacturing of Bayer biologics products.  Dr. Xia began her pharmaceutical industrial career at AXY Pharmaceuticals, which was acquired by Celera Genomics in 2001.  During the six years-service with AXY/Celera, she took on both scientific and managerial roles in drug discovery programs from target validation through IND enabling activities.  Dr. Xia received her B.S. degree in Biochemistry from Sun Yat-Sen University in China and earned her Ph.D. in Molecular Biology and Microbiology from the University of Newcastle upon Tyne in the U.K.  She did her postdoctoral research at University of Glasgow in the U.K. and cancer immune therapy research at University of Louisville Medical School in the U.S.  Founded in 2012, Akeso Biopharma aims to make therapeutic antibody drugs accessible and affordable to all patients through R&D and manufacturing innovation.  In 2015, Akeso signed a US$200 million agreement with Merck (MDS) by out-licensing a checkpoint clinical drug candidate to Merck.  Eight drug candidates developed by Akeso are currently in clinical stage.